| __timestamp | Cytokinetics, Incorporated | Galapagos NV |
|---|---|---|
| Wednesday, January 1, 2014 | 17268000 | 9079000 |
| Thursday, January 1, 2015 | 19667000 | 20309000 |
| Friday, January 1, 2016 | 27823000 | 16945000 |
| Sunday, January 1, 2017 | 36468000 | 20559000 |
| Monday, January 1, 2018 | 31282000 | 29641000 |
| Tuesday, January 1, 2019 | 39610000 | 88258000 |
| Wednesday, January 1, 2020 | 52820000 | 162170000 |
| Friday, January 1, 2021 | 96803000 | 167218000 |
| Saturday, January 1, 2022 | 177977000 | 239528000 |
| Sunday, January 1, 2023 | 173612000 | 94252000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. Over the past decade, Cytokinetics, Incorporated and Galapagos NV have demonstrated contrasting trends in their SG&A expenditures.
From 2014 to 2023, Cytokinetics saw a staggering increase of over 900% in their SG&A expenses, peaking in 2022. This surge reflects their aggressive expansion and investment in administrative capabilities. In contrast, Galapagos NV experienced a more volatile trajectory, with a significant spike in 2020, where expenses more than doubled compared to the previous year, before stabilizing in 2023.
These trends highlight the strategic differences between the two companies. While Cytokinetics focuses on steady growth, Galapagos NV appears to be navigating through periods of rapid change, possibly driven by strategic shifts or market conditions.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Galapagos NV
AbbVie Inc. and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: AstraZeneca PLC vs Galapagos NV
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Galapagos NV